Who
Gabriel Brooks
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Solid Biosciences.
In numbers
- Trades disclosed
- 43
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $601K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 18 Oct 2023
- Last trade
- 19 Oct 2026
- Last filed
- 20 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 20 Oct 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $25K4,374 at $5.62 | filing |
| 18 Oct 2026filed 20 Oct 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —9,750 | filing |
| 18 Oct 2026filed 20 Oct 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,750 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | —0 at $5.82 | filing |
| 18 Feb 2026filed 18 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | —0 at $5.82 | filing |
| 13 Feb 2026filed 18 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —10,937 | filing |
| 13 Feb 2026filed 18 Feb 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,937 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,937 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —10,937 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $81K12,616 at $6.44 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $81K12,616 at $6.44 | filing |
| 2 Feb 2026filed 2 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $182K28,335 at $6.44 | filing |
| 2 Feb 2026filed 2 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Sold | $182K28,335 at $6.44 | filing |
| 31 Jan 2026filed 2 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —28,225 | filing |
| 31 Jan 2026filed 2 Feb 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,225 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,225 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —28,225 | filing |
| 29 Jan 2026filed 21 Apr 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —58,847 at $0.00 | filing |
| 29 Jan 2026filed 21 Apr 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —58,847 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | SLDB Solid BiosciencesBiotechnology | SEC FORM 4 Code M | —58,847 | filing |
News
Solid Biosciences (NASDAQ:SLDB) Upgraded at UBS GroupSLDB · tickerreport.com · 17 Oct 2026Solid Biosciences (NASDAQ:SLDB) Stock Lifted to Strong-Buy by UBS GroupSLDB · tickerreport.com · 17 Oct 2026Solid Biosciences Inc. (NASDAQ:SLDB) Stock Has Average Price Target of $18.69SLDB · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Gabriel Brooks; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.